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Abstract:  Cytoskeleton  defines  the  shape  and  structural  organization  of  the  cell.  Its 
elements  participate  in  cell  motility,  intracellular  transport  and  chromosome  movement 
during  mitosis.  Papillomaviruses  (PV)  are  strictly epitheliotropic and  induce self-limiting 
benign tumors of skin and mucosa, which may progress to malignancy. Like many other 
viruses, PV use the host cytoskeletal components for several steps during their life cycle. 
Prior  to  internalization,  PV  particles  are  transported  along  filopodia  to  the  cell  body. 
Following  internalization,  retrograde  transport  along  microtubules  via  the  dynein  motor 
protein complex is observed. In addition, viral minichromosomes depend on the host cell 
machinery  for  partitioning  of  viral  genomes  during  mitosis,  which  may  be  affected  by 
oncoproteins E6 and E7 of high-risk human PV types. This mini-review summarizes recent 
advances in our understanding of papillomavirus’ interactions with the host cell cytoskeletal 
elements. 
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1. Introduction 
Papillomaviruses (PV) replicate exclusively in the terminally differentiating epidermal cells of skin 
and mucosa in a strictly species-specific manner (for review see [1]). They infect the basal cells of this 
tissue [2], to which they probably gain access via microlesions. Following delivery of viral DNA to the 
nucleus  of  infected  cells,  infection  is  established  by  the  initial  amplification  of  the  viral genome as 
nuclear minichromosomes. The infection spreads by cell division during which the viral genome copy 
number per cell remains constant. The viral life cycle is completed by amplification of the viral genome 
in fully differentiated cells, structural (late) gene expression, and viral assembly. Progeny virions are 
shed  within  the  dead  squames  of  the  terminally  differentiating  keratinocytes.  Human  PV  (HPV) 
comprises a large group of viruses with more than 100 genotypes identified so far. They usually induce 
benign self limiting tumors of skin and mucosa, which rarely progress to carcinomas of the cervix, 
vagina, penis, anus and others. Progression usually requires persistent infection by high risk types, like 
e.g., HPV16 and HPV18. Due to the high incidence of HPV in the general population, HPV infection is 
associated with more than 7% and 1% of cancers in women and men, respectively. 
PV  are  small  nonenveloped  viruses  with  icosahedral  symmetry.  Their  shell  is  composed  of  360 
molecules of the major capsid protein, L1, which are organized into 72 capsomeres, each comprised of 
a pentameric L1 assembly, forming a T = 7 icosahedral lattice [3]. In addition, up to 72 molecules of the 
minor  capsid  protein,  L2,  are  incorporated  into  a  virion  supporting  experimental  evidence  that  L2 
requires the pentameric L1 structure for interaction [4,5]. L2 is mainly hidden inside the capsid and only 
portions of the N-terminus (residues 60 to 120) are exposed on the capsid surface as determined by 
accessibility  to  antibody  binding  [6,7].  Additional  indirect  evidence  suggests  that  the  extreme  
N-terminus folds back into the capsid thus rendering it inaccessible to antibody binding and proteolytic 
cleavage  in  mature  virions  [8,9].  The  capsid  protects  a  circular  double  stranded  DNA  genome  of 
approximately 8000 bp, which is organized into chromatin.  
The  strict  dependence  of  PV  on  terminally  differentiating  keratinocytes  for  completion  of  their 
replication  cycle  initially  made  the  study  of  entry  processes  difficult.  First,  it  was  impossible  to 
propagate virions in cell culture, and viral yields from natural lesions were low, with some exceptions. 
The use of DNA-free virus-like particles (VLPs), virions generated in organotypic raft cultures and later 
pseudovirions harboring marker plasmids, which were generated using heterologous expression or cell-
free  packaging  systems,  helped  to  partially  overcome  this  deficiency  [10–17].  A  second  drawback 
hampering the study of PV entry, that is still not completely solved, is our inability to efficiently infect 
either organotypic raft cultures or primary keratinocytes in vitro [18] unless pseudovirions had been 
activated by furin precleavage of immature pseudovirions [19]. Therefore, researchers have had to rely 
on established cell lines, the most commonly used of which is the HaCaT cell line, to study PV binding 
and uptake. However, the recent development of an in vivo mouse model by the Schiller group will 
allow for the testing of observations made in vitro, despite the known deficiencies owing to switching 
species [2]. In this review we will focus on the role of the cytoskeleton in entry of high risk HPV type 
16  (HPV16)  and  closely  related  viruses.  Due  to  the  experimental  difficulties  outlined  above  our 
knowledge is still rather limited. However, good progress has been made recently. In vitro data backed 
by in vivo studies suggest an elaborate sequence of cell surface events that includes retrograde flow 
along actin protrusions towards the cell body. In addition, it has become obvious that PV have evolved Viruses 2011, 3                         
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unique strategies for internalization and intracellular trafficking to overcome the challenges it faces by 
replicating in this terminally differentiating, stratified epithelium. 
2. Summary of Current Knowledge  
2.1. Receptors 
In order to fully appreciate the role of cytoskeleton in PV entry, we have to briefly discuss primary 
and secondary receptors that are essential for initiating infectious internalization. The majority of PV 
types examined to date use heparan sulfate proteoglycans (HSPGs) as primary attachment receptors 
[20,21]. In HSPGs, unbranched oligosaccharides composed of alternating disaccharide units of uronic 
acid  and  glucosamine  are  linked  to  a  protein  core  (syndecans,  glypicans,  perlecans)  (reviewed  in 
[22,23]). The carbohydrate chains are modified by sulfation to varying degree at the 2-O, 3-O, and  
6-O position of the uronic acid and at the 3-O and 6-O position of the amino sugar. In addition, the 
amino  group  of  the  glucosamine  may  be  either  acetylated  or  sulfated.  HSPGs  can  be  cell  surface 
associated (syndecans, glypicans) or secreted into the extracellular space (perlecans). In vivo studies 
using a cervicovaginal mouse model as well as in vitro studies suggest that genital HPV types, like 
HPV16, preferentially bind to the basement membrane and extracellular matrix (ECM), respectively. 
Even though binding to ECM-resident non-HSPG receptors has been demonstrated for some types  
in vitro, especially for HPV11, productive binding of HPV16 and HPV18 seems to require interaction 
with heparan sulfates [24–27]. Initial attachment is mediated by the major capsid protein L1 [28]. Some 
published evidence indicates distinct secondary interactions of L1 with HSPGs may occur subsequent to 
primary attachment [27,29]. Support for this came recently from the crystal structure of HPV16 and 
HPV18 L1 capsomeres in complex with heparin oligomers [30]. Four different modes of binding were 
seen with two binding sites each at the tip and the vertex of the capsomere. At least two L1 molecules 
within a capsomere contribute to a single binding site. Mutation of just one of these binding sites in 
HPV16 completely abolished both binding to ECM and cell surfaces [28,30], whereas exchanges in the 
other binding sites severely impaired infectivity without significantly reducing primary attachment [30]. 
This set of data suggests a secondary engagement of heparin binding sites. Not all HPV types may use 
HSPG as receptors. Raft-derived HPV31 virions were reported to not require HSPG interaction for 
infection  of  keratinocytes  in  vitro  [31],  however,  HPV31  pseudovirions  require  HSPG  in  the 
cervicovaginal  mouse  model,  similar  to  HPV16  [26].  Also,  HPV5  infection  was  not  sensitive  to  
addition of heparan sulfates in vitro despite having detectable interaction [32]. However, it was blocked 
by  heparan  sulfates  in  the  in  vivo  model,  albeit  with  seemingly  different  requirements  regarding  
sulfation [26]. 
2.2. Cell Surface Events 
Two recent studies addressed the question of how the ECM/basement bound virions might be picked 
up by basal cells in order to gain cell entry. The Ozbun group reported that HPV31 virions induced a 
pronounced reorganization of the actin cytoskeleton after virus binding [33]. Cortical actin network and 
stress fiber break down was observed within 5 min of binding, followed by an induction of filopodia at 
30  min  post  binding.  Reorganization  required  signaling  via  tyrosine  kinase  and  phosphoinositide  3 Viruses 2011, 3                         
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(PI3)-kinase. In addition, HPV31 infection was blocked by treatment with inhibitors of tyrosine and PI3 
kinases. In the presence of inhibitors like genistein and wortmannin, virions were retained on the cell 
surface suggesting that signaling and cytoskeleton rearrangement is important for infectious entry. It 
was also shown that virions are taken up from ECM via retrograde transport along filopodia, filopodial 
retraction, and lateral curling of filopodia during which the filopodial tip was bent back towards the cell 
body.  Indirect  evidence  that  these  transport  processes  occur  on  the  cell  surface  came  from 
neutralization studies following treatment with kinase inhibitors. More direct evidence for cell surfing of 
HPV16  virions  along  filopodia  towards  the  cell  body  prior  to  internalization  was  provided  by  the 
Helenius group [34]. Here, electron microscopy and acid washes of FITC-labeled virions were used to 
demonstrate association of virions with the outer surface of filopodia. Fluorescence video microscopy 
was  used  to  investigate  virion  transport  along  cell  protrusions.  The  HPV16  virion  transport  speed 
matched the speed of F-actin retrograde flow. Actin flow requires three activities: polymerization of 
actin at the tip, anchored myosin II-mediated retrograde transport, and depolymerization at the cell 
body. Transport via actin was confirmed by the sensitivity of HPV16 directed flow to inhibitors of actin 
polymerization  and  depolymerization  as  well  as  to  myosin  II  inhibitors.  Additional  observations 
suggested  that  retrograde  transport  was  probably  receptor-mediated.  Virions  showed  directional 
movement at two different speeds, 1.6 and 2.9 μm/min, which indicates that transport occurs along two 
different kinds of actin protrusions. Directional movement was only observed along protrusions and not 
on the cell body. Furthermore, HPV16 pseudoinfection was impaired in scarce cell cultures treated with 
the myosin II inhibitor blebbistatin. Inhibition was not observed when dense cultures were infected, 
which have significantly lower numbers of actin protrusions. These findings indicate that retrograde 
transport on the cell surface contributes to efficient HPV16 infection. Indirectly, these data also suggest 
that virions are only internalized after they reach the cell body. It has become clear in recent years that a 
not yet identified secondary non-HSPG receptor is involved in infectious internalization of PV particles 
[8,27]. Which receptor links the virion to F-actin has not been addressed yet. It seems more likely that 
HSPGs play a role in this, as the handoff to the secondary receptor occurs rather late, directly before 
infectious internalization, and requires conformational changes affecting both capsid proteins. However, 
it was reported that conformational changes resulting in the exposure of the L2 N-terminus might occur 
at the basement membrane without requiring interaction with cell surfaces [35]. 
Attachment-induced conformational changes in L1 are not well defined yet but seem to involve the 
surface loop linking the antiparallel B and C β-strands [29,36], which are part of the capsomere core. 
Interaction with HSPG also induces a more clearly defined conformational change that results in the 
exposure  of  the  L2  N-terminus  [8].  This  makes  a  highly  conserved  consensus  furin  convertase 
recognition site accessible for cleavage by furin convertase [37]. The cellular peptidyl-prolyl cis/trans 
isomerase Cyclophilin B (CyPB), which is associated with cell surface HSPG [38,39], facilitates the 
exposure of the L2 N-terminus [40]. Indirect evidence suggests that conformational changes reduce 
affinity of virions to HS, thus aiding the handover to the secondary receptor [8].  
Evolution of such an elaborate process for gaining access to the basal cells may be warranted by the 
difficulties PV faces. First, PV infect the basal cells of the target tissue. These are believed to be the 
only cells within this tissue that support the establishment of PV infection. Second, access to these cells 
can only be efficiently achieved via microlesions. Thus, binding to receptors specific to the basement Viruses 2011, 3                         
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membrane  prevents  unproductive  interactions  with  differentiated  cells  higher  up  in  the  tissue.  In 
addition, virions will be preferentially taken up by basal cells migrating into the wound. During wound 
healing, these cells are triggered to allow for increased cell division, which again improves the likelihood 
of a successful infection. 
2.3. Endocytosis 
Probably owing to the complex events on the basement membrane and cell surface discussed above, 
internalization of PV is unusually slow and highly asynchronous. Internalization half times have been 
reported to range from 4 h for HPV16 to 14 h for HPV31 and HPV33 [20,41–43]. Evidence suggests 
that individual HPV types may use different endocytic pathways. Despite some contradictory reports, it 
has become clear in recent years that HPV16 is internalized via a clathrin-, caveolin-, and dynamin-
independent novel pathway [44,45]. Entry and infection is resistant to individual and combined siRNA-
mediated  down  regulation  of  caveolin-1  and  clathrin  heavy  chain  as  well  as  to  over-expression  of 
dominant-negative  mutants  of  dynamin-2,  caveolin-1,  and  eps-15  (EGF  receptor  pathway  substrate 
clone No. 15, which plays a role in clathrin coated vesicle formation) [45]. The use of a large library of 
siRNAs and inhibitors to interfere with known factors of endocytosis also excluded flotillin- and lipid 
raft-dependent endocytosis as well as macropinocytosis and phagocytosis as possible mechanisms of 
internalization  [44].  Confirming  early  reports  using  VLPs  [46],  pseudovirions  were  found  in  wide 
uncoated pits up to 100 nm in diameter [44]. As of yet, this entry pathway has not been characterized 
any  further  but  may  utilize  tetraspanin-enriched  microdomains  (TEM)  as  entry  platforms.  HPV16 
pseudovirions accumulate at TEMs at the cell body, where they co-localize with keratinocytes-specific 
tetraspanin CD151. In addition, HPV16 infection is partially sensitive to treatment with CD151-specific 
antibody  and  siRNA  [45].  This  observation  provides  further  support  for  the  notion  that  
internalization  might  be  restricted  to  the  cell  body  [34].  BPV1  was  reported  to  utilize  a  
clathrin-dependent  endocytic  pathway  for  infectious  uptake  based on a combination of microscopic 
analyses and biochemical inhibition of known pathways [47–49]. In contrast, HPV31 endocytosis seems 
to occur via caveolae [41,50]. However, one study found that treatment with chlorpromazine but not 
with  inhibitors  of  caveolar  uptake  prevented  HPV31  pseudovirus  infection  [51].  Additional,  more 
systemic studies are required to address these discrepancies.  
2.4. Cytosolic Transport 
Passage through the cell membrane is followed by transport across the cytoplasm, uncoating, and 
nuclear entry of the genome. As outlined above, actin plays a critical role in endocytosis, not only being 
essential for cell surfing but probably also for cross-linking of receptor-ligand complexes as well as 
budding and release of endocytic vesicles from the plasma membrane [52]. Microtubules, in contrast, 
are involved in later steps including vesicular transport from early to late endosomes. Two early studies 
have  analyzed  the  function  of  microtubules  for  these  processes.  Using  HPV33  pseudovirions  and 
various inhibitors, it was observed that actin is involved early in infection, whereas microtubules act at a 
later stage [53]. These results were essentially confirmed and extended using bovine PV type 1 (BPV1) 
virions and RT-PCR to assay infection [48]. Another study of BPV1 entry utilized immunofluorescence 
and  electron  microscopy.  Liu  et  al.  [54]  observed  virions  in  close  association  with  microtubules Viruses 2011, 3                         
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immediately after infection of CV-1 cells. When the cells were kept at 37 °C, L1 protein accumulated in 
a perinuclear region. When the temperature was shifted from 37 °C to 4 °C or when cells were treated 
with nocodazole shortly after viral entry, leading to depolymerization of microtubules, BPV1 remained 
in  numerous  small  vesicle-like  structures  scattered  throughout  the  cytoplasm.  However,  a 
comprehensive study of vesicular intracellular trafficking of different PV types in normal keratinocytes 
is still lacking. Given the divergent reports regarding the endocytic mechanisms, it is not surprising that 
the subject of intracellular trafficking of PV-containing vesicles and the cellular compartments involved 
is also highly controversial [55]. 
There  is  near  consensus  that  successful  infection  requires  acidification  of  endocytic  vesicles 
suggesting  that  PV  particles  must  pass  through  the  endosomal  compartment  [45,48,53,56].  It  is 
believed that acidification is important for uncoating, which is required for the segregation of L1 protein 
from the L2/DNA complex. L1 protein accumulates in the lysosomal compartment, where it is probably 
degraded,  whereas  the  L2/DNA  complex  escapes  the  endosomal  compartment  [57].  
This  requires  functional  L2  protein.  Blockage  of  furin  cleavage  at  the  cell  surface  by  mutation  or 
inhibitors  [37],  inhibition  of  γ-secretase  via  an  unknown  mechanism  [58,59],  and  mutations  in  a 
membrane-destabilizing domain of L2 [57] all prevent endosomal escape and abrogate infection. 
Recent evidence suggests that microtubules play an important role in transport of viral genome not 
only during vesicular transport but also following egress from endosomes. The carboxyl-terminal 40 
amino acids of HPV16 and HPV33 L2 were demonstrated to interact with the dynein motor protein 
complex, which mediates retrograde transport along microtubules. Mutational analysis suggested that 
this  interaction  is  important  for  efficient  infection  [60].  Using  yeast  two-hybrid  screens,  
co-immunoprecipitation, and immunofluorescence, Schneider et al. identified dynein subunits DYNLT1 
and DYNLT3 as interaction partners of L2 [61]. The importance of these factors for HPV16 infection 
was  confirmed  by  cytosolic  delivery  of  DYNLT1-  and  DYNLT3-specific  inhibitory  antibodies  and 
siRNA. 
The issue of how the papillomaviral genome transits from the cytosol to the nucleus has not been 
systematically addressed. However, co-delivery of L2 and genome to the nucleus have been reported 
for HPV16 and BPV1, perhaps in conjunction with a cell-encoded chaperone [60]. Nuclear envelope 
breakdown is required for establishment of HPV16 infection indicating that active nuclear import via 
nuclear pore complexes may not be required [62]. However, it is unknown how the L2/DNA complex is 
retained in the reforming nuclei. It is undisputed that L2 protein accompanies the viral genome to the 
nucleus. L2 and the viral genome co-localize in the nucleus at PML nuclear bodies (PML NB; also 
called ND10 domains) following infection [63]. Efficient early PV transcription as well as transcription 
of the pseudoviral genome under the control of the CMV immediate early promoter requires either 
intact PML NB or expression of the PML protein [63]. However, mechanistic explanations for these 
observations have not been provided as of yet. 
2.5. The Role of Cytoskeleton during Late Events  
PV utilize the cytoskeleton at late stages of the viral life cycle as well. Viral genomes are maintained 
in infected cells as extrachromosomal elements. Following establishment of infection with up to 100 
copy numbers, viral genome amplification on average is restricted to approximately once per S phase Viruses 2011, 3                         
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resulting in a fairly constant copy number. During mitosis, viral minichromosomes attach to the cellular 
chromosomes via the E2 protein. Thus, they rely on the host cell machinery for partitioning of genomes 
during  cell  division  ensuring  that  both  daughter  cells  retain  equal  numbers  of  the  viral  genome. 
However,  PV  types  have  evolved  divergent  strategies  for  tethering  their  genome  to  cellular 
chromosomes. BPV1 tethers the genome in complex with the cellular bromodomain protein, Brd4, via 
the  transactivating  domain  of  E2  [64],  whereas  HPV8  associates  with  regions  of  ribosomal  DNA 
repeats located on the short arm of acrocentric chromosomes using an interaction domain located in the 
hinge region of E2 [65]. These findings have recently been reviewed in detail [66].  
The viral E6 and E7 oncoproteins also influence chromosomal segregation by inducing centrosome 
aberrations [67]. E6 protein has been shown to trigger centrosome accumulation [68]; E7 protein, on 
the other hand, can cause centrosome overduplication [67]. Since these processes are mainly observed 
in persistently infected and/or transformed cells aberrations may be due to uncontrolled expression of 
both oncoproteins and may not occur in the productive life cycle. However, it is possible that they also 
occur late in the viral life cycle and go unnoticed due to the terminal differentiation process. Recent 
reviews have addressed the processes underlying these observations in more detail [69–71]. 
Vegetative viral genome amplification is observed in fully differentiated cells of the upper spinous 
cell layer in cells that are usually incompetent for DNA replication. This is followed by expression of 
late proteins, including the E4 protein, and virion assembly. Since these terminally differentiating cells 
completely  degrade  their  nuclei  and  viruses  are  released  from  the  dying  cells,  cytoskeleton  is  not 
believed  to  play  any  role  in  the  egress  of  progeny  virions  in  contrast  to  many  other  viruses  [72]. 
However, differentiated keratinocytes of the layer allowing late gene expression are highly keratinized. 
The dense keratin network has been proposed to hamper the release of progeny virus. A number of 
reports  provide  strong  evidence  that  E4  protein,  which  is  the  most  highly  expressed  viral  protein, 
induces the depletion of keratin from these cells [73,74]. Keratin depletion is probably achieved by 
phosphorylation and ubiquitylation of differentiation-dependent and -independent keratins, which results 
in targeting of keratins for proteasomal degradation and keratin network disruption.  
3. Conclusions  
The development in recent years of novel experimental systems and tools has greatly enhanced our 
current understanding of the complex papillomaviral life cycle. However, many open questions remain. 
Hopefully, more systemic use of current technology and availability of improved and additional model 
systems  in  the  future  will  allow  answering  the  remaining  questions  to  shed  more  light  onto  this 
fascinating group of human and animal pathogens. 
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